Please go to the PowerPak homepage
and select a course.
Improving Efficacy in First-Line Treatment of Advanced Melanoma:
Focus on the Role of Immune Checkpoint Inhibitors
This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Bristol Myers Squibb.
Registration & Dates for Activities
Tuesday, November 29, 2022
3:00 - 3:30 PM ET
Jordan P. McPherson, PharmD, MS, BCOP
Oncology Clinical Pharmacist, Melanoma & Non-melanoma Skin Cancer
Huntsman Cancer Institute
Adjunct Assistant Professor
University of Utah College of Pharmacy
Salt Lake City, Utah
Dr. McPherson has disclosed that he has received funds for Contracted Research from Hitachi, LTD.
Susanne Batesko, RN, BSN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
All relevant financial relationships have been mitigated.
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credits: 0.5 hour (0.05 ceu)
Estimated time to complete activity: 30 minutes
Location: From the convenience of your home or business; accessible via both PC and MAC
Fee Information: There is no fee for this educational activity.
Type of Activity: Knowledge
This accredited activity has been designed for oncology pharmacists.
HOW TO EARN CREDIT
Participants must 1) read the learning objectives and faculty disclosures; 2) attend and participate in the live webinar; and 3) complete the posttest and evaluation form directly after the event with a maximum of within 60 days of attending the live session. To answer the questions, click on your selected choice for each answer then proceed to the next question. Your credit will automatically uploaded to CPE Monitor.
The goal of this PowerUp Recap session is to provide learners a summary of the 2-part, case-based monographs series titled, Improving Efficacy in First-Line Treatment of Advanced Melanoma: Focus on the Role of Immune Checkpoint Inhibitors.
Part 1: Optimal Treatment of Advanced Melanoma in the First-line Setting
https://www.powerpak.com/course/preamble/122795 (expires November 20, 2022)
Part 2: Managing Adverse Events of First-line Treatment of Advanced Melanoma
https://www.powerpak.com/course/preamble/122796 (expires November 20, 2022)
The goal of monograph series is to provide oncology pharmacists with advanced and up-to-date knowledge of new clinical evidence for the use of immune checkpoint inhibitors (ICIs) in advanced melanoma, including mechanisms of drug action, approved indications, use in first-line therapy, and adverse drug effects, which will serve to optimize patient outcomes and quality of life.
During the Recap session, leaners will have the opportunity to ask Dr. McPherson questions about the use of ICIs in the treatment of advanced melanoma.
Upon completion of this activity, the participant should be better able to:
- Recognize the role for immune checkpoint inhibitors as monotherapy and in combination with chemotherapy in the first-line setting for advanced melanoma
- Describe approaches to recognize and manage patients' immune-related adverse events in advanced melanoma
Presentation (15 minutes)
Q&A (15 minutes)
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, or Bristol Myers Squibb. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA.